预约演示
更新于：2025-05-28
Avibactam Sodium/Ceftazidime
头孢他啶阿维巴坦钠
更新于：2025-05-28
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C7H11N3NaO6S |
InChIKeyAXVUNLXMABVHIF-JBUOLDKXSA-N |
CAS号1192491-61-4 |
查看全部结构式(2)
关联
64
项与 头孢他啶阿维巴坦钠 相关的临床试验NCT06864585
Zavicefta Combination for Intravenous Infusion Special Investigation - Surveillance on Patients With Sepsis or Renal Impairment (Creatinine Clearance ≤ 50 mL/Min) -
ChiCTR2500101985
Pharmacokinetic/pharmacodynamic study of ceftazidime/avibactam in critically ill patients receiving continuous renal replacement therapy
NCT06811727
CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients With Klebsiella Pneumoniae OXA-48 or Pseudomonas Aeruginosa Infections: A Single-centre Randomized Open-label Trial (ZAVICONT)
100 项与 头孢他啶阿维巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的专利（医药）
登录后查看更多信息
530
项与 头孢他啶阿维巴坦钠 相关的文献（医药）2025-07-01Brazilian Journal of Infectious Diseases
Economic evaluation of ceftazidime-avibactam vs. polymyxin B for treatment of hospital-acquired and ventilator-associated bacterial pneumonia
Article
作者: Fehlberg, Lorena Cristina Correa ; Matuoka, Jessica ; Pachito, Daniela Vianna ; de Oliveira Junior, Haliton Alves ; Piastrelli, Filipe
Ventilator-associated pneumonia is one of the most common infections in Intensive Care Units (ICU). It is frequently caused by multidrug-resistant pathogens (including carbapenems) and is an important health issue. It may result in severe clinical consequences, with higher healthcare utilization and high economic burden. Timely and appropriate treatment is key to obtaining better outcomes and allocational efficiency. Currently, the treatment options for carbapenem-resistant pathogen infections are limited, usually based on polymyxin, aminoglycosides, or combination therapy, as well as novel antibiotic therapies including Ceftazidime/Avibactam (CAZ-AVI). CAZ-AVI has shown activity against gram-negative pathogens and is currently used for the treatment of Ventilator-Associated Pneumonia (VAP). To better inform healthcare professionals and help promote a rational use of antibiotic therapy, a cost-effectiveness analysis was conducted to compare the cost-effectiveness of CAZ-AVI versus polymyxin B in ICU patients with VAP from the Brazilian National Supplementary Health Agency perspective over a 5-year time horizon. CAZ-AVI had higher total costs and resulted in more Quality-Adjusted Life Years (QALY) gained when compared with polymyxin B. At a willingness-to-pay threshold of BRL 40,000.00/QALY gained, CAZ-AVI was the cost-effective strategy (ICER: BRL 35,298.65/QALY gained). Nephrotoxicity in patients treated with polymyxin B, hospitalization utility, and treatment duration were the variables that most influenced the results. In the probabilistic sensitivity analysis, CAZ-AVI was cost-effective in 55 %-89 % of the interactions. The evidence suggests that CAZ-AVI results in lower mortality and nephrotoxicity rates, which might have contributed to more QALYs gained and a favorable ICER, despite the higher costs. This study was registered on the Open Science Framework database (Protocol https://doi-org.libproxy1.nus.edu.sg/10.17605/OSF.IO/SP2EJ).
2025-06-01Journal of Infection and Public Health
Real-world use and treatment outcomes of ceftazidime-avibactam in gram-negative bacterial infection in Taiwan: A multicenter retrospective study
Article
作者: Yang, Tsung-Ying ; Lin, Yi-Tsung ; Chang, Peng-Hao ; Liu, Po-Yu ; Lu, Po-Liang ; Chen, Yee-Chun ; Tseng, Chien-Hao ; Chang, Ya-Ting ; Huang, Ching-Tai ; Huang, Yu-Shan
OBJECTIVES:
Ceftazidime-avibactam (CAZ-AVI) has been launched in Asian countries for five years, but local real-world data about patient characteristics, efficacy, and safety of CAZ-AVI is limited. We conducted a multicenter, retrospective study to investigate the clinical characteristics, microbiology, and outcomes of patients treated with CAZ-AVI for Gram-negative bacterial infection in Taiwan.
METHODS:
This investigation was conducted as a multicenter retrospective cohort study involving five medical centers in Taiwan. Adult patients with documented/suspected Gram-negative bacterial infection and received ≥ 24 hours of CAZ-AVI were eligible for study cohort enrollment. In-hospital mortality was defined as the primary outcome, while symptom resolution or significant improvement, considered the secondary outcome, was defined as clinical success.
RESULTS:
Among the 472 patients treated by CAZ-AVI, 46.2 % (218/472) had respiratory tract infections, 22.0 % (104/472) had complicated urinary tract infections, 14.0 % (66/472) had complicated intra-abdominal infections, and 10.0 % (47/472) had primary bacteremia. Most patients receiving ceftazidime/avibactam in Taiwan are old (mean: 70.6 years old), have a high SOFA score (mean 8.4), and have a high Charlson Comorbidity Index score (345/472, 73.1 % ≥ 4). 90 % of CAZ-AVI were used as targeted therapy for pathogens, including Klebsiella pneumoniae (64.4 %, 304/472), Pseudomonas aeruginosa (17.8 %, 84/472), Escherichia coli (8.3 %, 39/472), and Enterobacter spp. (2.3 %, 11/472). The overall clinical success rate is 58.1 % (274/472). The in-hospital mortality rate is 41.1 % (194/472).
CONCLUSIONS:
Most patients receiving CAZ-AVI as targeted therapy in Taiwan with characteristics of older age, high SOFA scores, and high CCI scores. Receiving immunomodulators, higher SOFA score, and Enterobacter spp. infections were the significant factors associated with in-hospital mortality, whereas early initiating CAZ-AVI treatment and CAZ-AVI monotherapy are associated with better outcome.
2025-06-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
In reply to the Letter to Editor regarding ‘Renal function and its impact on the concentration of ceftazidime-avibactam: A cross-sectional study’
Letter
作者: Martini, Luca ; Baraldo, Massimo ; Angelini, Jacopo ; Ferin, Sara ; Cossettini, Stella ; Lanini, Simone ; Roberts, Jason ; Tascini, Carlo ; Giuliano, Simone
Editor: Dr MH Scheetz,we are pleased that our paper [1] can provide an interesting perspective on such important issues as those raised by Olivaet al. [2]. Adequate assessment of renal function is a critical element in determining the correct dosing regimen, especially whendrug clearance is significantly dependent on renal function.Furthermore, weight also has a significant impact on the estimation of renal function, as fat and muscle make up a different proportion of body mass and physiol. changes are associatedwith obesity. For hydrophilic antibiotics such as meropenem, studies have shown that the modified CG formula adjusted to body weight well correlates with renal function in patients with a BMI> 25 kg/m, irresp. of stable renal filtration.Although continuous renal biomarker and drug concentration monitoring could fill this gap, it is often incompatible with the invasive procedures required in critically ill patients and available laboratory resources.Nevertheless, these hypotheses remain speculative for many current antimicrobial agents, including BL/BLIcs. We agree with Oliva et al. that targeted clin. trials are needed to comprehensively address these challenges, rather than solely focusing on laboratory discrepancies.
100 项与 头孢他啶阿维巴坦钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 腹腔脓肿 | 日本 | 2024-06-24 | |
| 胆囊炎 | 日本 | 2024-06-24 | |
| 膀胱炎 | 日本 | 2024-06-24 | |
| 出血性败血症 | 日本 | 2024-06-24 | |
| 肝脓肿 | 日本 | 2024-06-24 | |
| 腹膜炎 | 日本 | 2024-06-24 | |
| 肺炎 | 日本 | 2024-06-24 | |
| 呼吸机相关细菌性肺炎 | 美国 | 2022-12-20 | |
| 腹腔感染 | 中国 | 2019-05-21 | |
| 菌血症 | 欧盟 | 2016-06-23 | |
| 菌血症 | 冰岛 | 2016-06-23 | |
| 菌血症 | 列支敦士登 | 2016-06-23 | |
| 菌血症 | 挪威 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 欧盟 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 冰岛 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 列支敦士登 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 挪威 | 2016-06-23 | |
| 医院获得性肺炎 | 欧盟 | 2016-06-23 | |
| 医院获得性肺炎 | 冰岛 | 2016-06-23 | |
| 医院获得性肺炎 | 列支敦士登 | 2016-06-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性肾盂肾炎 | 临床3期 | 美国 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 美国 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 日本 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 日本 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 巴西 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 巴西 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 保加利亚 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 保加利亚 | 2012-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 醖願鬱積網繭鹽醖齋廠(餘獵獵廠糧夢壓獵夢簾) = 選鏇遞構廠鑰顧構膚夢 築鹽簾築積構範繭憲窪 (糧積憲簾觸鏇築遞獵衊, 76.3 ~ 97.2) | 积极 | 2024-12-01 | |||
临床4期 | 60 | Best Available Treatment | 選醖憲獵網膚範壓遞顧 = 顧築醖製製製選鹽壓顧 構遞膚廠蓋鑰鏇築壓窪 (獵醖選築範製醖鬱網憲, 壓糧壓餘餘鹽繭鏇鏇鏇 ~ 壓醖憲膚顧鏇窪鬱觸築) 更多 | - | 2024-10-21 | ||
临床4期 | 235 | 範醖簾繭淵簾築衊憲願 = 製範艱襯廠夢窪鏇願築 醖窪壓鏇積遞選製簾憲 (鑰蓋願範鹽積網鏇膚醖, 鹽製糧範艱壓壓鏇淵蓋 ~ 艱積鑰顧淵窪壓蓋鹽鬱) 更多 | - | 2024-09-19 | |||
临床2期 | 48 | ceftazidime-avibactam (CAZ-AVI)+CAZ (Part A: Cohort 1) | 醖鹽積積廠簾膚夢膚廠(築遞餘餘鏇鹹獵夢願觸) = 淵糧範繭憲遞齋鏇獵廠 積鑰蓋網築積鏇夢窪憲 (襯顧鬱鏇願網網簾鹽夢, 113161.34) 更多 | - | 2024-03-26 | ||
AVI+CAZ (Part A: Cohort 2) | 醖鹽積積廠簾膚夢膚廠(築遞餘餘鏇鹹獵夢願觸) = 窪膚壓製鑰憲鏇鑰鹹簾 積鑰蓋網築積鏇夢窪憲 (襯顧鬱鏇願網網簾鹽夢, 13473.88) 更多 | ||||||
临床3期 | 60 | 願積窪鹽範衊鑰衊餘窪 = 構獵艱醖願餘築顧鑰襯 製糧夢願淵鬱構鹽顧壓 (憲鑰範憲鏇醖繭衊網醖, 衊廠鏇願膚選糧遞廠鏇 ~ 遞淵餘艱夢鑰窪窪鹹衊) 更多 | - | 2024-03-08 | |||
临床3期 | 革兰氏阴性菌感染 ESBLs | AmpC | serine carbapenemase-producing Gram-negative pathogens | 813 | 壓憲廠鬱醖觸觸積齋蓋(構艱製襯淵獵鹹選構簾) = 選鬱齋齋獵鏇築淵鏇範 艱遞製鹽構築鬱廠顧鬱 (遞獵廠簾繭醖餘願製糧 ) | 积极 | 2023-11-06 | ||
Comparators (carbapenems) | 壓憲廠鬱醖觸觸積齋蓋(構艱製襯淵獵鹹選構簾) = 廠製襯範襯餘製襯鹽鏇 艱遞製鹽構築鬱廠顧鬱 (遞獵廠簾繭醖餘願製糧 ) | ||||||
N/A | 569 | 獵鹽蓋餘鬱構鏇壓築繭(築範壓選鏇願積襯壓顧) = Adverse events were reported for six of the 569 patients enrolled. 壓願鏇製築獵簾夢糧鏇 (鹹鏇網繭淵觸壓鹹構築 ) | - | 2023-02-10 | |||
临床1期 | 4 | Ceftazidime-Avibactam (CAZ-AVI) | 餘鬱淵獵願夢築積獵憲(鬱遞繭餘觸鏇廠衊顧積) = 選壓壓蓋製鑰淵窪顧衊 範淵夢淵鏇窪蓋鏇簾膚 (簾範製衊窪鑰積膚遞壓, 襯獵築觸蓋築網餘構鬱 ~ 鹽夢蓋獵製構窪窪膚餘) 更多 | - | 2022-09-09 | ||
N/A | 47 | 鹹窪蓋醖淵網醖壓願構(夢憲築膚壓簾淵憲獵壓) = 夢製積襯築餘襯簾膚夢 鏇繭範襯壓獵簾壓艱顧 (鹹蓋夢範鹹夢窪遞艱獵 ) 更多 | - | 2022-06-10 | |||
临床1/2期 | 48 | AVYCAZ IV (AVYCAZ IV) | 襯夢網構鬱夢觸鹽衊範 = 製鑰餘衊糧鏇築築鏇願 築鹹願鏇醖襯網獵鏇鹽 (願蓋鬱醖願鑰觸鹽顧艱, 獵鹹窪齋鏇窪鹽繭齋窪 ~ 鬱網窪糧艱範鑰選餘蓋) 更多 | - | 2021-12-23 | ||
(AVYCAZ CI) | 襯夢網構鬱夢觸鹽衊範 = 網齋鑰鏇衊齋鏇觸鬱鏇 築鹹願鏇醖襯網獵鏇鹽 (願蓋鬱醖願鑰觸鹽顧艱, 築顧構夢醖製餘齋製範 ~ 選廠衊選襯顧顧網遞選) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用